119:(CRC). He translated these findings into clinical practice by discovering the molecular landscape of response and resistance to EGFR, HER2 and NTRK1 blockades in CRC. One of the main focuses of his research is the study of the emergence and evolution of drug-resistant clones that can be restrained to improve the efficacy of anticancer agents to develop therapies that adapt to a tumour's evolution. His group used several approaches in their work, including genetic analysis of clinical samples, a large collection of CRC cellular models, patient-derived xenografts (xenopatients), and liquid biopsies. In the last years his studies uncovered the molecular bases of primary and acquired resistance to anti-EGFR therapies in colorectal tumours. These findings have been rapidly translated into clinically applicable predictive biomarkers, which represent the first example of personalized medicine for colorectal tumours and are used to select patients for therapy.
20:
159:
Bardelli has authored more than 200 scientific articles, of which 100 were written as an independent investigator. His research papers have been cited over 40,000 times. Bardelli has been listed as a Highly Cited
Researcher in the field of Clinical Medicine in
355:
Siravegna, Giulia; Lazzari, Luca; Crisafulli, Giovanni; Sartore-Bianchi, Andrea; Mussolin, Benedetta; Cassingena, Andrea; Martino, Cosimo; Lanman, Richard B.; Nagy, Rebecca J.; Fairclough, Stephen; Rospo, Giuseppe (2018-07-09).
413:
Siravegna, Giulia; Mussolin, Benedetta; Buscarino, Michela; Corti, Giorgio; Cassingena, Andrea; Crisafulli, Giovanni; Ponzetti, Agostino; Cremolini, Chiara; Amatu, Alessio; Lauricella, Calogero; Lamba, Simona (July 2015).
299:
Bardelli, Alberto; Parsons, D. Williams; Silliman, Natalie; Ptak, Janine; Szabo, Steve; Saha, Saurabh; Markowitz, Sanford; Willson, James K. V.; Parmigiani, Giovanni; Kinzler, Kenneth W.; Vogelstein, Bert (2003-05-09).
791:
Medico, Enzo; Russo, Mariangela; Picco, Gabriele; Cancelliere, Carlotta; Valtorta, Emanuele; Corti, Giorgio; Buscarino, Michela; Isella, Claudio; Lamba, Simona; Martinoglio, Barbara; Veronese, Silvio (2015-04-30).
1093:
Germano, Giovanni; Lamba, Simona; Rospo, Giuseppe; Barault, Ludovic; Magrì, Alessandro; Maione, Federica; Russo, Mariangela; Crisafulli, Giovanni; Bartolini, Alice; Lerda, Giulia; Siravegna, Giulia (2017-12-07).
1259:
725:
Misale, Sandra; Bozic, Ivana; Tong, Jingshan; Peraza-Penton, Ashley; Lallo, Alice; Baldi, Federica; Lin, Kevin H.; Truini, Mauro; Trusolino, Livio; Bertotti, Andrea; Di
Nicolantonio, Federica (2015-09-22).
659:
Arena, Sabrina; Siravegna, Giulia; Mussolin, Benedetta; Kearns, Jeffrey D.; Wolf, Beni B.; Misale, Sandra; Lazzari, Luca; Bertotti, Andrea; Trusolino, Livio; Adjei, Alex A.; Montagut, Clara (2016-02-03).
593:
Russo, Mariangela; Lamba, Simona; Lorenzato, Annalisa; Sogari, Alberto; Corti, Giorgio; Rospo, Giuseppe; Mussolin, Benedetta; Montone, Monica; Lazzari, Luca; Arena, Sabrina; Oddo, Daniele (2018-06-12).
528:
Russo, Mariangela; Misale, Sandra; Wei, Ge; Siravegna, Giulia; Crisafulli, Giovanni; Lazzari, Luca; Corti, Giorgio; Rospo, Giuseppe; Novara, Luca; Mussolin, Benedetta; Bartolini, Alice (January 2016).
130:
in CRC. His studies are built on an unconventional approach that an increased dynamic and mutational load in CRC cells can rouse an otherwise slack immune response, a vital requisite for effective
30:(born 29 November 1967) is an Italian geneticist and cancer researcher, expert in the field of precision medicine. He is a full professor of histology at the Department of Oncology,
1323:
69:. Here Bardelli began studying the genomics of cancer. During his postdoctoral training at Johns Hopkins, Bardelli published multiple papers in high-profile journals such as
80:
In 2004, he returned to Italy as director of a research unit dedicated to the study of tumour genomes at the
Candiolo Cancer Institute and Dept. of Oncology,
46:
on 29 November 1967. He studied
Biological Sciences at the University of Turin and received his master's degree in 1991. After graduation, he moved to the
1308:
134:. Bardelli's team tweaked the clonal evolution of the tumour, via a pharmacological intervention, to provoke the persistent renewal of neoantigens.
1313:
1230:
144:
molecular heterogeneity and clonal evolution, both inter-patient and intra-tumour, to overcome the resistance to targeted therapies, and
662:"MM-151 overcomes acquired resistance to cetuximab and panitumumab in colorectal cancers harboring EGFR extracellular domain mutations"
137:
Bardelli's studies have been reported in high peer-reviewed scientific journals as Cancer Cell, Nature, JAMA, and Lancet
Oncology.
187:
206:
596:"Reliance upon ancestral mutations is maintained in colorectal cancers that heterogeneously evolve during targeted therapies"
471:
Van
Emburgh, Beth O.; Sartore-Bianchi, Andrea; Di Nicolantonio, Federica; Siena, Salvatore; Bardelli, Alberto (2014-09-12).
47:
1318:
151:
Bardelli's team is composed of more than 20 members, including biologists, PH students, technicians and bioinformatics.
140:
Currently, Bardelli's team uses colorectal cancer models to establish personalized treatment for patients, focusing on:
274:
62:
103:
Since April 2022, he has been the scientific director of IFOM, the AIRC Institute of
Molecular Oncology, Milan.
1303:
1288:
250:
1205:
794:"The molecular landscape of colorectal cancer cell lines unveils clinically actionable kinase targets"
358:"Radiologic and Genomic Evolution of Individual Metastases during HER2 Blockade in Colorectal Cancer"
225:
51:
177:
58:
93:
He is a member of the scientific committee of the
Italian Association for Cancer Research (AIRC).
90:
From 2018 to 2020, he served as president of the
European Association for Cancer Research (EACR).
1298:
1157:
1238:
728:"Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers"
416:"Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients"
147:
immunotherapy to manipulate the patient's immune system and to find new therapeutic options.
1293:
1181:
1107:
1041:
805:
739:
607:
867:
Siravegna, Giulia; Marsoni, Silvia; Siena, Salvatore; Bardelli, Alberto (September 2017).
8:
81:
31:
1111:
1045:
809:
743:
611:
1139:
1075:
956:
923:
904:
849:
768:
727:
707:
636:
595:
575:
505:
472:
448:
415:
395:
337:
131:
127:
1143:
1131:
1123:
1096:"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth"
1067:
1059:
1010:
1002:
961:
943:
896:
888:
853:
841:
833:
773:
755:
711:
699:
691:
641:
623:
567:
559:
510:
492:
453:
435:
387:
379:
329:
321:
116:
97:
579:
399:
341:
1115:
1079:
1049:
992:
951:
935:
908:
880:
823:
813:
763:
747:
681:
673:
631:
615:
549:
541:
500:
484:
443:
427:
369:
313:
924:"Blood circulating tumor DNA for non-invasive genotyping of colon cancer patients"
87:
Since 2016, he has been a full professor of histology at the
University of Turin.
939:
677:
545:
488:
66:
997:
374:
619:
161:
884:
470:
1282:
1127:
1063:
1006:
947:
892:
837:
759:
695:
627:
563:
496:
439:
383:
325:
123:
317:
50:
in London and obtained a PhD in Biochemistry and Molecular Biology from the
34:
and Scientific Director of IFOM, the AIRC Institute of Molecular Oncology.
1135:
1095:
1071:
1029:
1014:
980:
965:
900:
868:
845:
793:
777:
703:
661:
645:
571:
530:"Acquired Resistance to the TRK Inhibitor Entrectinib in Colorectal Cancer"
529:
514:
457:
391:
357:
333:
301:
354:
173:
2020 Guido Venosta Award, FIRC AIRC, Presidenza della Repubblica Italiana
19:
1119:
828:
818:
751:
686:
554:
57:
From 1999 to 2004, Bardelli has been a postdoctoral researcher at the
473:"Acquired resistance to EGFR-targeted therapies in colorectal cancer"
1054:
431:
302:"Mutational analysis of the tyrosine kinome in colorectal cancers"
111:
Bardelli performed the first comprehensive mutational profile of
412:
112:
1158:"Scopus preview - Bardelli, Alberto - Author details - Scopus"
866:
43:
1206:"Johns Hopkins inducts new members into Society of Scholars"
724:
658:
1030:"Medical research: Personalized test tracks cancer relapse"
869:"Integrating liquid biopsies into the management of cancer"
790:
298:
592:
1260:"II sezione: scienze della biologia animale e dell'uomo"
1092:
186:
2017 Fellow of European Molecular Biology Organization (
527:
1324:
Officers of the Order of Merit of the Italian Republic
193:
2015 Fellow of the European Academy of Cancer Sciences
922:Siravegna, Giulia; Bardelli, Alberto (March 2016).
921:
1280:
96:In 2005, he co-founded the gene editing company
979:Bardelli, Alberto; Pantel, Klaus (2017-02-13).
1231:"Fellows| European Academy of Cancer Sciences"
978:
981:"Liquid Biopsies, What We Do Not Know (Yet)"
196:2015 Fellow of the Turin Academy of Sciences
65:, Baltimore (MD/USA), in the group led by
1309:Italian expatriates in the United Kingdom
1053:
996:
955:
827:
817:
767:
685:
635:
553:
504:
447:
373:
1027:
205:Bardelli was appointed "Officer" of the
18:
1281:
207:Order of Merit of the Italian Republic
183:2017 ESMO Translational Research Award
122:Bardelli also investigated the use of
1182:"Alberto Bardelli's Publons profile"
48:Ludwig Institute for Cancer Research
1314:Alumni of University College London
13:
14:
1335:
873:Nature Reviews. Clinical Oncology
232:(in Italian). University of Turin
1028:Bardelli, Alberto (2017-05-24).
1252:
1223:
1198:
1174:
1150:
1086:
1021:
972:
915:
860:
784:
718:
652:
63:Howard Hughes Medical Institute
666:Science Translational Medicine
586:
521:
464:
406:
348:
292:
267:
243:
218:
1:
212:
42:Alberto Bardelli was born in
1264:www.accademiadellescienze.it
1235:www.europeancanceracademy.eu
940:10.1016/j.molonc.2015.12.005
678:10.1126/scitranslmed.aad5640
546:10.1158/2159-8290.CD-15-0940
489:10.1016/j.molonc.2014.05.003
154:
7:
998:10.1016/j.ccell.2017.01.002
375:10.1016/j.ccell.2018.06.004
176:2019 Elected Member of the
106:
61:School of Medicine and the
10:
1340:
1319:University of Turin alumni
620:10.1038/s41467-018-04506-z
200:
885:10.1038/nrclinonc.2017.14
230:Dipartimento di Oncologia
167:
52:University College London
37:
226:"Prof. Alberto Bardelli"
162:Clarivate Web of Science
59:Johns Hopkins University
318:10.1126/science.1082596
251:"IFOM Alberto Bardelli"
24:
1304:Scientists from Turin
798:Nature Communications
732:Nature Communications
600:Nature Communications
22:
1289:Italian oncologists
1120:10.1038/nature24673
1112:2017Natur.552..116G
1046:2017Natur.545..417B
810:2015NatCo...6.7002M
744:2015NatCo...6.8305M
612:2018NatCo...9.2287R
180:Society of Scholars
164:(2014, 2018–2020).
82:University of Turin
32:University of Turin
928:Molecular Oncology
819:10.1038/ncomms8002
752:10.1038/ncomms9305
477:Molecular Oncology
132:immunosurveillance
128:precision medicine
117:colorectal cancers
25:
16:Italian geneticist
1106:(7683): 116–120.
1040:(7655): 417–418.
368:(1): 148–162.e7.
98:Horizon Discovery
1331:
1274:
1273:
1271:
1270:
1256:
1250:
1249:
1247:
1246:
1237:. Archived from
1227:
1221:
1220:
1218:
1217:
1202:
1196:
1195:
1193:
1192:
1178:
1172:
1171:
1169:
1168:
1154:
1148:
1147:
1090:
1084:
1083:
1057:
1025:
1019:
1018:
1000:
976:
970:
969:
959:
919:
913:
912:
864:
858:
857:
831:
821:
788:
782:
781:
771:
722:
716:
715:
689:
672:(324): 324ra14.
656:
650:
649:
639:
590:
584:
583:
557:
534:Cancer Discovery
525:
519:
518:
508:
483:(6): 1084–1094.
468:
462:
461:
451:
410:
404:
403:
377:
352:
346:
345:
296:
290:
289:
287:
286:
275:"Tutti i membri"
271:
265:
264:
262:
261:
247:
241:
240:
238:
237:
222:
28:Alberto Bardelli
23:Alberto Bardelli
1339:
1338:
1334:
1333:
1332:
1330:
1329:
1328:
1279:
1278:
1277:
1268:
1266:
1258:
1257:
1253:
1244:
1242:
1229:
1228:
1224:
1215:
1213:
1204:
1203:
1199:
1190:
1188:
1180:
1179:
1175:
1166:
1164:
1156:
1155:
1151:
1091:
1087:
1055:10.1038/545417a
1026:
1022:
977:
973:
920:
916:
865:
861:
789:
785:
723:
719:
657:
653:
591:
587:
526:
522:
469:
465:
432:10.1038/nm.3870
420:Nature Medicine
411:
407:
353:
349:
297:
293:
284:
282:
273:
272:
268:
259:
257:
249:
248:
244:
235:
233:
224:
223:
219:
215:
203:
170:
157:
109:
67:Bert Vogelstein
40:
17:
12:
11:
5:
1337:
1327:
1326:
1321:
1316:
1311:
1306:
1301:
1296:
1291:
1276:
1275:
1251:
1222:
1197:
1173:
1162:www.scopus.com
1149:
1085:
1020:
991:(2): 172–179.
971:
934:(3): 475–480.
914:
879:(9): 531–548.
859:
783:
717:
651:
585:
520:
463:
426:(7): 795–801.
405:
347:
291:
266:
242:
216:
214:
211:
202:
199:
198:
197:
194:
191:
184:
181:
174:
169:
166:
156:
153:
149:
148:
145:
126:as a tool for
108:
105:
39:
36:
15:
9:
6:
4:
3:
2:
1336:
1325:
1322:
1320:
1317:
1315:
1312:
1310:
1307:
1305:
1302:
1300:
1299:Living people
1297:
1295:
1292:
1290:
1287:
1286:
1284:
1265:
1261:
1255:
1241:on 2019-07-04
1240:
1236:
1232:
1226:
1211:
1207:
1201:
1187:
1183:
1177:
1163:
1159:
1153:
1145:
1141:
1137:
1133:
1129:
1125:
1121:
1117:
1113:
1109:
1105:
1101:
1097:
1089:
1081:
1077:
1073:
1069:
1065:
1061:
1056:
1051:
1047:
1043:
1039:
1035:
1031:
1024:
1016:
1012:
1008:
1004:
999:
994:
990:
986:
982:
975:
967:
963:
958:
953:
949:
945:
941:
937:
933:
929:
925:
918:
910:
906:
902:
898:
894:
890:
886:
882:
878:
874:
870:
863:
855:
851:
847:
843:
839:
835:
830:
825:
820:
815:
811:
807:
803:
799:
795:
787:
779:
775:
770:
765:
761:
757:
753:
749:
745:
741:
737:
733:
729:
721:
713:
709:
705:
701:
697:
693:
688:
683:
679:
675:
671:
667:
663:
655:
647:
643:
638:
633:
629:
625:
621:
617:
613:
609:
605:
601:
597:
589:
581:
577:
573:
569:
565:
561:
556:
551:
547:
543:
539:
535:
531:
524:
516:
512:
507:
502:
498:
494:
490:
486:
482:
478:
474:
467:
459:
455:
450:
445:
441:
437:
433:
429:
425:
421:
417:
409:
401:
397:
393:
389:
385:
381:
376:
371:
367:
363:
359:
351:
343:
339:
335:
331:
327:
323:
319:
315:
312:(5621): 949.
311:
307:
303:
295:
280:
276:
270:
256:
252:
246:
231:
227:
221:
217:
210:
208:
195:
192:
189:
185:
182:
179:
178:Johns Hopkins
175:
172:
171:
165:
163:
152:
146:
143:
142:
141:
138:
135:
133:
129:
125:
124:immunotherapy
120:
118:
114:
104:
101:
99:
94:
91:
88:
85:
83:
78:
76:
72:
68:
64:
60:
55:
53:
49:
45:
35:
33:
29:
21:
1267:. Retrieved
1263:
1254:
1243:. Retrieved
1239:the original
1234:
1225:
1214:. Retrieved
1212:. 2019-04-10
1209:
1200:
1189:. Retrieved
1185:
1176:
1165:. Retrieved
1161:
1152:
1103:
1099:
1088:
1037:
1033:
1023:
988:
984:
974:
931:
927:
917:
876:
872:
862:
801:
797:
786:
735:
731:
720:
669:
665:
654:
603:
599:
588:
540:(1): 36–44.
537:
533:
523:
480:
476:
466:
423:
419:
408:
365:
361:
350:
309:
305:
294:
283:. Retrieved
281:(in Italian)
278:
269:
258:. Retrieved
254:
245:
234:. Retrieved
229:
220:
204:
158:
150:
139:
136:
121:
110:
102:
95:
92:
89:
86:
79:
74:
70:
56:
41:
27:
26:
1294:1967 births
1186:publons.com
985:Cancer Cell
829:2434/338945
687:10230/26180
606:(1): 2287.
555:2434/342140
362:Cancer Cell
279:www.airc.it
255:www.ifom.eu
1283:Categories
1269:2021-05-14
1245:2021-05-14
1216:2021-05-14
1191:2021-05-14
1167:2021-05-14
285:2021-05-14
260:2021-05-14
236:2021-05-14
213:References
1144:205262351
1128:1476-4687
1064:1476-4687
1007:1878-3686
948:1878-0261
893:1759-4782
854:205337164
838:2041-1723
760:2041-1723
712:206689568
696:1946-6242
628:2041-1723
564:2159-8290
497:1878-0261
440:1546-170X
384:1878-3686
326:1095-9203
209:in 2021.
155:Citations
1136:29186113
1072:28541318
1015:28196593
966:26774880
901:28252003
846:25926053
804:: 7002.
778:26392303
738:: 8305.
704:26843189
646:29895949
580:33819773
572:26546295
515:24913799
458:26030179
400:51611215
392:29990497
342:85934154
334:12738854
107:Research
1210:The Hub
1108:Bibcode
1080:4385197
1042:Bibcode
957:5528968
909:1478003
806:Bibcode
769:4595628
740:Bibcode
637:5997733
608:Bibcode
506:5528615
449:4868598
306:Science
201:Honours
113:kinases
75:Science
54:(UCL).
1142:
1134:
1126:
1100:Nature
1078:
1070:
1062:
1034:Nature
1013:
1005:
964:
954:
946:
907:
899:
891:
852:
844:
836:
776:
766:
758:
710:
702:
694:
644:
634:
626:
578:
570:
562:
513:
503:
495:
456:
446:
438:
398:
390:
382:
340:
332:
324:
168:Awards
71:Nature
38:Career
1140:S2CID
1076:S2CID
905:S2CID
850:S2CID
708:S2CID
576:S2CID
396:S2CID
338:S2CID
44:Turin
1132:PMID
1124:ISSN
1068:PMID
1060:ISSN
1011:PMID
1003:ISSN
962:PMID
944:ISSN
897:PMID
889:ISSN
842:PMID
834:ISSN
774:PMID
756:ISSN
700:PMID
692:ISSN
642:PMID
624:ISSN
568:PMID
560:ISSN
511:PMID
493:ISSN
454:PMID
436:ISSN
388:PMID
380:ISSN
330:PMID
322:ISSN
188:EMBO
73:and
1116:doi
1104:552
1050:doi
1038:545
993:doi
952:PMC
936:doi
881:doi
824:hdl
814:doi
764:PMC
748:doi
682:hdl
674:doi
632:PMC
616:doi
550:hdl
542:doi
501:PMC
485:doi
444:PMC
428:doi
370:doi
314:doi
310:300
115:in
1285::
1262:.
1233:.
1208:.
1184:.
1160:.
1138:.
1130:.
1122:.
1114:.
1102:.
1098:.
1074:.
1066:.
1058:.
1048:.
1036:.
1032:.
1009:.
1001:.
989:31
987:.
983:.
960:.
950:.
942:.
932:10
930:.
926:.
903:.
895:.
887:.
877:14
875:.
871:.
848:.
840:.
832:.
822:.
812:.
800:.
796:.
772:.
762:.
754:.
746:.
734:.
730:.
706:.
698:.
690:.
680:.
668:.
664:.
640:.
630:.
622:.
614:.
602:.
598:.
574:.
566:.
558:.
548:.
536:.
532:.
509:.
499:.
491:.
479:.
475:.
452:.
442:.
434:.
424:21
422:.
418:.
394:.
386:.
378:.
366:34
364:.
360:.
336:.
328:.
320:.
308:.
304:.
277:.
253:.
228:.
100:.
84:.
77:.
1272:.
1248:.
1219:.
1194:.
1170:.
1146:.
1118::
1110::
1082:.
1052::
1044::
1017:.
995::
968:.
938::
911:.
883::
856:.
826::
816::
808::
802:6
780:.
750::
742::
736:6
714:.
684::
676::
670:8
648:.
618::
610::
604:9
582:.
552::
544::
538:6
517:.
487::
481:8
460:.
430::
402:.
372::
344:.
316::
288:.
263:.
239:.
190:)
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.
